Home・Stock List・Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc

Closed

0.85 -3.41

Buy Sell

Overview

Share price change

24h

Current

Min

0.85

Max

0.86

Key metrics
By Trading Economics
Income	418K -5.5M
EPS	-0.18
Profit margin	-6,600
Employees	25
EBITDA	906K -5.3M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+365.12% upside

Dividends
By Acuity
Next Earnings	6 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-9.9M 28M
Previous open	4.26
Previous close	0.85

Actinium Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

25 Jul 2026, 23:51 UTC

Correlated Moves

Bitcoin is trading higher during Saturday's session, building on Friday's gains. The price movement aligns with Ethereum's upward trend.

25 Jul 2026, 23:42 UTC

Personal Income MoM Data Release on July 30, 2026, Forecasts Modest Growth Amid Ongoing Market Volatility and Geopolitical Concerns.

25 Jul 2026, 23:42 UTC

U.S. Personal Spending Expected to Rise 0.4% in June Amid Inflation and Geopolitical Tensions Impacting Consumer Behavior

25 Jul 2026, 23:42 UTC

Market Awaits Key PCE Price Index Data on July 30, 2026, Amid Rising Inflation Concerns and Potential Impact on Federal Reserve Policy.

25 Jul 2026, 23:42 UTC

South Korea's exports surge 70.9% in June, with August release expected to reveal continued growth amid cautious investor sentiment due to inflation and geopolitical tensions.

25 Jul 2026, 23:42 UTC

U.S. GDP Price Index Set for 3.7% Increase Amid Cautious Optimism and Inflation Concerns Ahead of Key Federal Reserve Policy Decisions.

25 Jul 2026, 23:42 UTC

Traders Brace for PCE Price Index Release Amid Geopolitical Tensions and Inflation Concerns, Anticipating 0.4% Increase

25 Jul 2026, 23:42 UTC

Core PCE Price Index MoM Release on July 30, 2026, Expected to Show Modest 0.1% Increase Amid Inflation Concerns and Market Sensitivity.

25 Jul 2026, 23:42 UTC

U.S. Q2 2026 GDP Growth Rate Release Expected at 2.3% Amid Positive Economic Sentiment and Geopolitical Concerns

25 Jul 2026, 23:32 UTC

S&P/Case-Shiller Home Price Index Set for July Release Amidst Cautious Market Sentiment and Inflation Concerns

25 Jul 2026, 23:32 UTC

South Africa's upcoming balance of trade data on July 31, 2026, is under scrutiny as analysts anticipate continued deficits amid rising imports and geopolitical tensions.

25 Jul 2026, 23:31 UTC

"Cryptocurrency Gains Amid Geopolitical Tensions; European Stocks Shift and Fed's Rate Decision Looms"

25 Jul 2026, 23:31 UTC

Cryptocurrency gains amid European market reassessment and bond turmoil, as investors brace for the Fed's interest rate decision and Japan's fiscal policy shift.

25 Jul 2026, 23:31 UTC

Bitcoin and Ethereum rise amid shifting European equity markets, Japan's fiscal policy changes, and looming Federal Reserve interest rate decision.

25 Jul 2026, 23:31 UTC

Cryptocurrency prices rise as Bitcoin and Ethereum gain, while European equity markets face shifts and Japan's fiscal policy change looms ahead of the Federal Reserve's interest rate decision.

25 Jul 2026, 23:24 UTC

Mexico's Q2 GDP Growth Rate Release on July 30 Sparks Cautious Optimism Amid Strong Services PMI Performance.

25 Jul 2026, 23:24 UTC

Brazil's Unemployment Rate Expected to Remain Stable or Improve in June 2026 Amid Cautious Optimism and Economic Recovery Concerns

25 Jul 2026, 23:13 UTC

Mexico's Q2 2026 GDP Growth Rate Release on July 30 Sparks Caution Amid Geopolitical Tensions and Trade Tariff Concerns.

25 Jul 2026, 23:13 UTC

Japan's Industrial Production MoM data for June 2026 set to release on July 30, with a modest increase of 0.7% anticipated amid mixed economic sentiment and rising inflation concerns.

25 Jul 2026, 23:13 UTC

Germany's Inflation Rate Release on July 30, 2026: Market Anticipates Continued Pressure Amid Mixed Economic Signals.

25 Jul 2026, 23:13 UTC

Japan's Retail Sales Expected to Rise 2.8% YoY Amid Concerns Over Consumer Spending and Economic Recovery Challenges

25 Jul 2026, 23:13 UTC

Germany's July Inflation Rate Expected to Rise 0.7% Amid Mixed Economic Sentiment and Rising Oil Prices

25 Jul 2026, 23:03 UTC

Wholesale Inventories MoM Advance Data Set for Release Amid Mixed Economic Sentiment and Geopolitical Tensions, Forecasting 0.2% Increase.

25 Jul 2026, 23:03 UTC

U.S. Goods Trade Balance Release Expected to Show $98 Billion Deficit Amid Tariff Concerns and Inflation Pressures

25 Jul 2026, 23:03 UTC

U.S. Retail Inventories Ex Autos Data Release on July 28, Amid Weakening Consumer Spending and Inflation Concerns

25 Jul 2026, 23:01 UTC

Avalanche continues to trade higher, reflecting strong performance since Friday's close. Earlier, it peaked over 8%, remaining above its 20-day moving average.

25 Jul 2026, 22:51 UTC

Japan's June 2026 unemployment rate forecast at 2.5% amid rising inflation concerns and market volatility ahead of release on July 30, signaling mixed investor sentiment.

25 Jul 2026, 22:42 UTC

Durable Goods Orders Report on July 27, 2026 Expected to Show Recovery Amidst Market Volatility and Geopolitical Tensions.

25 Jul 2026, 22:42 UTC

U.S. Durable Goods Orders Ex Transportation Expected to Rise 0.9% in June Amid Cautious Optimism and External Economic Pressures

25 Jul 2026, 22:42 UTC

Mortgage Rates Hit 6.69% Amid Rising Treasury Yields and Inflation Concerns, Influencing Real Estate Market Dynamics

Peer Comparison

Price change

Actinium Pharmaceuticals Inc Forecast

Price Target

By TipRanks

365.12% upside

12 Months Forecast

Average 4 USD 365.12%

High 4 USD

Low 4 USD

Based on 1 Wall Street analysts offering 12 month price targets forActinium Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Actinium Pharmaceuticals Inc - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.